Telix Pharmaceuticals reported full-year 2025 revenue of US$803.8 million, up 56% year-over-year, driven by strong growth in its Precision Medicine segment and the successful U.S. launch of Gozellix. The company issued 2026 revenue guidance of US$950-970 million and advanced multiple regulatory filings and late-stage pipeline programs.
A phase I trial and a preclinical study found viral immunotherapy triggered T cell responses in glioblastoma. The clinical study enrolled 41 patients; the mouse study showed prolonged survival and immunologic memory.
The blood-brain barrier continues to block most treatments for glioblastoma and central nervous system diseases, with only 0.01% of biologic drugs reaching the brain. New intellectual property coverage and synthetic methods aim to address delivery challenges.
Telix Pharmaceuticals submitted a marketing authorization application in Europe for TLX101-Px, a glioma imaging agent, on February 18, 2026. The filing covers major European markets and a U.S. NDA submission will follow.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07579208 |
A Phase1 Clinical Trial Evaluating Locoregional Delivery Of Engineered NK Cells Containing IL13Ra And EGFvIII Chimeric Antigen Receptor (CAR), IL-21 Secretion And Deleted TGF-BetaR2 And NR3C1 In Recurrent Glioblastoma |
NOT_YET_RECRUITING | PHASE1 |
| NCT07551336 |
Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma |
RECRUITING | PHASE1 |
| NCT07541781 |
Sitagliptin in Recurrent/Progressive Grade 4 Glioma |
NOT_YET_RECRUITING | PHASE1 |
| NCT07538128 |
Evaluating Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab for Recurrent Glioblastoma |
RECRUITING | EARLY_PHASE1 |
| NCT07480941 |
Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma |
RECRUITING | PHASE1 |
| NCT07416188 |
Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma |
RECRUITING | PHASE1/PHASE2 |
| NCT07346144 |
Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma |
RECRUITING | PHASE1/PHASE2 |
| NCT07297212 |
A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma |
RECRUITING | PHASE2 |
| NCT07209241 |
Different Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBM |
RECRUITING | PHASE1 |
| NCT07193628 |
B7H3/IL13Ra2 Bispecific Armored Chimeric Antigen Receptor T-Cell Therapy Study for Recurrent/Refractory Glioblastoma |
RECRUITING | PHASE1 |
